Drug Type Small molecule drug |
Synonyms ABBV 525, ABBV525 |
Target |
Mechanism MALT1 inhibitors(Mucosa-associated lymphoid tissue lymphoma translocation protein 1 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-Cell Malignant Neoplasm | Phase 1 | US | 04 Apr 2023 | |
B-Cell Malignant Neoplasm | Phase 1 | AU | 04 Apr 2023 | |
B-Cell Malignant Neoplasm | Phase 1 | BE | 04 Apr 2023 | |
B-Cell Malignant Neoplasm | Phase 1 | FR | 04 Apr 2023 | |
B-Cell Malignant Neoplasm | Phase 1 | IL | 04 Apr 2023 | |
B-Cell Malignant Neoplasm | Phase 1 | ES | 04 Apr 2023 | |
B-Cell Malignant Neoplasm | Phase 1 | GB | 04 Apr 2023 | |
Chronic Lymphocytic Leukemia | Phase 1 | US | 04 Apr 2023 | |
Chronic Lymphocytic Leukemia | Phase 1 | AU | 04 Apr 2023 | |
Chronic Lymphocytic Leukemia | Phase 1 | BE | 04 Apr 2023 |